TableĀ 2

The raw data of the comparison between Idylla and Ion Torrent NGS for BRAF, KRAS and NRAS testing

Case No.Tumour contentKRAS Ion NGSKRAS IDYLLANRAS Ion NGSNRAS IDYLLABRAF Ion NGSBRAF IDYLLA
180%WTWTG12DG12DWTWT
270%WTWTG12DG12DWTWT
370%WTWTWTWTV600EV600D/E
470%WTWTWTWTV600EV600D/E
550%WTWTWTWTV600EV600D/E
650%WTWTWTWTV600EV600D/E
750%WTWTWTWTV600EV600D/E
870%WTWTQ61RQ61RWTWT
950%WTWTG12DG12DWTWT
1070%G12DG12DWTWTWTWT
1150%G12DG12DWTWTWTWT
1250%G12VG12VWTQ61LWTWT
1360%G12DG12DWTWTWTWT
1460%N/ANot testedWTWTV600EV600D/E
1570%N/ANot testedWTFailedV600EFailed
1630%N/ANot testedWTWTV600EV600D/E
1750%N/ANot testedWTWTV600EV600D/E
1850%N/ANot testedG12CG12CWTWT
1980%Q61KQ61KN/ANot testedN/ANot tested
2050%G12VG12VN/ANot testedN/ANot tested
2150%G12DG12DN/ANot testedN/ANot tested
2270%G12DG12DN/ANot testedN/ANot tested
2350%G12CG12CN/ANot testedN/ANot tested
  • The Ion AmpliSeq Cancer Hotspot Panel was compared with the Idylla NRAS-BRAF-EGFRS492R Mutation Assay and the Iydlla KRAS Mutation Test. Not all cases were tested with both Idylla assays. Tumour percentage given is the minimum estimate.

  • NGS, next-generation sequencing; WT, wild type.